Enthera’s ‘Regenerative Immunology’ Approach Breaks New Ground In Diabetes And IBD
Exclusive Interview With CEO Giovanni Amabile
Executive Summary
Italy’s Enthera Pharmaceuticals is targeting a novel stem cell apoptosis pathway involved in several autoimmune diseases, with the aim of restoring cell and organ functions to their original state. The biotech recently closed a €35m series A financing round, the largest the country has seen to date.